PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2228273

Autologous transfusion.

L Stehling
View original source ↗Export metadata ↓

Abstract

Autologous transfusion is but one component of the comprehensive blood conservation program. It is often appropriate to employ more than one method of autologous transfusion. In addition, use of pharmacological measures to decrease blood loss, meticulous attention to surgical hemostasis, acceptance of lower hemoglobin levels during the perioperative period, and seeking the advice of transfusion medicine experts in assessing the need for administration of blood components are also important. Finally, the risks of homologous blood transfusion should not overshadow the life-saving benefits of transfusion.

Explore related subjects

Blood Transfusion, AutologousCell SeparationCosts and Cost AnalysisHumansIntraoperative PeriodUnited StatesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Stehling. 1990. Autologous transfusion.. https://doi.org/10.1097/00004311-199002840-00003

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Autologous serum therapy of the ocular surface with novel delivery by platelet concentrate gel.

Application of autologous serum to treat a multitude of ocular surface diseases and conditions is a relatively new technique that has gained popularity over the past 10 years. This review focuses on the use of topical autologous serum and a new platelet gel delivery technique that utilizes autologous platelet concentrate mixed with calcium chloride and thrombin for gelling serum, which can then be applied easily to the corneal surface. Residual platelet serum concentrate can be mixed with artificial tears that are capable of gelling in a 25% concentrate, which is then used by the patient postoperatively. A review of the literature identifies various concentrations of autologous serum, frequency of application, and storage criteria.

Blood Transfusion, Autologous↗
PubMed2006

Pneumonia as a complication of blood product transfusion in the critically ill: transfusion-related immunomodulation (TRIM).

BACKGROUND: An increased risk of postoperative infection (including pneumonia) attributable to the receipt of allogeneic blood transfusion has been investigated as a possible manifestation of transfusion-related immunomodulation (TRIM) in 16 randomized controlled trials (RCTs) and approximately 40 observational studies. OBJECTIVES: This review categorizes RCTs and observational studies with regard to the inference that they permit about possible mediators of TRIM-allogeneic white cells (WBCs), WBC-derived soluble mediators, and/or allogeneic plasma-and examines whether the totality of the clinical evidence supports an association between allogeneic blood transfusion and postoperative infection. RESULTS: When all available studies are considered together in meta-analyses, three types of studies show no increased risk of postoperative infection in association with allogeneic blood transfusion: a) RCTs comparing recipients of buffy-coat-reduced and prestorage-filtered, WBC-reduced allogeneic red cells; b) RCTs comparing recipients of allogeneic and autologous blood; and c) observational studies comparing patients transfused before and after implementation of WBC reduction. RCTs comparing recipients of nonbuffy-coat-reduced and WBC-reduced red blood cells may point to a TRIM effect, but they cannot yet be subjected to formal meta-analysis. CONCLUSIONS: No overwhelming clinical evidence has been presented to establish the existence of a TRIM effect that relates allogeneic blood transfusion to postoperative infection.

Blood Transfusion, Autologous↗